Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma.

A P Venook1

  • 1Division of Hematology and Oncology, University of California, San Francisco, 400 Parnassus Avenue, Suite 502, San Francisco, CA 94143, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

ESMO open·2025
Same author

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

British journal of cancer·2013
Same author

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

British journal of cancer·2005
Same author

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Therapeutic approaches to metastasis confined to the liver.

Current oncology reports·2001
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Early detection of hepatocellular carcinoma (HCC) is possible in high-risk patients. However, HCC often presents as incurable, and current treatments for unresectable tumors show limited survival benefits.

Area of Science:

  • Hepatology
  • Oncology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) surveillance is feasible in at-risk populations.
  • Optimal HCC surveillance strategies remain undetermined.
  • HCC is frequently diagnosed at an incurable stage, even with surveillance.

Purpose of the Study:

  • To review the current landscape of hepatocellular carcinoma detection and management.
  • To discuss treatment options for unresectable HCC.
  • To emphasize the importance of clinical trials for HCC treatment.

Main Methods:

  • Review of existing literature on HCC surveillance and treatment.
  • Analysis of surgical resection, transplantation, and ablative techniques.
  • Evaluation of palliative therapies for unresectable HCC.

Related Experiment Videos

Main Results:

  • Surgical resection is the preferred treatment but often not feasible due to disease extent and underlying liver conditions.
  • Liver transplantation and ablative therapies offer curative potential for selected unresectable cases.
  • Chemotherapy, hormonal therapy, and regional treatments provide palliative care but do not extend survival.

Conclusions:

  • Early HCC detection is achievable, but curative treatment remains challenging.
  • Management of unresectable HCC requires careful consideration of transplantation or ablative options.
  • Participation in clinical trials is recommended for patients with HCC to explore novel therapies and improve outcomes.